Trial · NCT03703375
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) Based on Local Assessment | Oral Azacitidine | 5.6 | 95% Confidence Interval 2.66 to 7.26 | Months | |
| Progression Free Survival (PFS) Based on Local Assessment | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) | 2.8 | 95% Confidence Interval 1.87 to 4.83 | Months | |
| Overall Survival (OS) | Oral Azacitidine | 18.4 | 95% Confidence Interval 12.88 to 31.47 | Months | |
| Overall Survival (OS) | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) | 10.3 | 95% Confidence Interval 4.24 to 13.50 | Months | |
| Progression Free Survival (PFS) Based on IRC Assessment | Oral Azacitidine | 4.2 | 95% Confidence Interval 2.66 to 5.88 | Months | |
| Progression Free Survival (PFS) Based on IRC Assessment | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) | 3.2 | 95% Confidence Interval 2.10 to 4.83 | Months | |
| Overall Response Rates (ORR) | Oral Azacitidine | Cycle 3 | 33.3 | 95% Confidence Interval 19.6 to 49.5 | Percentage of participants |
| Overall Response Rates (ORR) | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) | Cycle 3 | 43.2 | 95% Confidence Interval 28.3 to 59.0 | Percentage of participants |
| Overall Response Rates (ORR) | Oral Azacitidine | Cycle 6 | 31.0 | 95% Confidence Interval 17.6 to 47.1 | Percentage of participants |
| Overall Response Rates (ORR) | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) | Cycle 6 | 22.7 | 95% Confidence Interval 11.5 to 37.8 | Percentage of participants |
| Complete Response Rate (CRR) | Oral Azacitidine | Cycle 3 | 11.9 | 95% Confidence Interval 4.0 to 25.6 | Percentage of participants |
| Complete Response Rate (CRR) | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) | Cycle 3 | 22.7 | 95% Confidence Interval 11.5 to 37.8 | Percentage of participants |
| Complete Response Rate (CRR) | Oral Azacitidine | Cycle 6 | 11.9 | 95% Confidence Interval 4.0 to 25.6 | Percentage of participants |
| Complete Response Rate (CRR) | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) | Cycle 6 | 15.9 | 95% Confidence Interval 6.6 to 30.1 | Percentage of participants |
| Duration of Response (DOR) | Oral Azacitidine | 10.4 | 95% Confidence Interval 2.56 to NA | Percentage of participants | |
| Duration of Response (DOR) | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) | 3.4 | 95% Confidence Interval 2.00 to NA | Percentage of participants | |
| Time to Response (TTR) | Oral Azacitidine | 3 | Full Range 3 to 6 | Months | |
| Time to Response (TTR) | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) | 2.7 | Full Range 1 to 4 | Months | |
| Progression Free Survival 2 (PFS2) on Local Assessment | Oral Azacitidine | 11.0 | 95% Confidence Interval 6.44 to 18.89 | Months | |
| Progression Free Survival 2 (PFS2) on Local Assessment | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) | 6.7 | 95% Confidence Interval 3.52 to 9.56 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03703375/results